Susan M. Peters-Arentsen

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

From cell lines to PDXs: in vivo confirmation of synergistic drug responses identified in leukemia cell line models.

From cell lines to PDXs: in vivo confirmation of synergistic drug responses identified in leukemia cell line models.

Journal: Blood neoplasia

Published: September 03, 2025

Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia.

Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia.

Journal: International journal of molecular sciences

Published: May 03, 2024

Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia.

Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia.

Journal: Communications biology

Published: March 12, 2024

Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia.

Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia.

Journal: Experimental hematology & oncology

Published: August 09, 2023

CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in KMT2A-Rearranged Acute Lymphoblastic Leukemia.

CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in KMT2A-Rearranged Acute Lymphoblastic Leukemia.

Journal: International journal of molecular sciences

Published: July 02, 2023

High-Throughput Drug Library Screening in Primary KMT2A-Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 Signaling.

High-Throughput Drug Library Screening in Primary KMT2A-Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 Signaling.

Journal: Biomedicines

Published: January 28, 2022

High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemia.

High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemia.

Journal: Translational oncology

Published: January 22, 2021

Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia.

Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia.

Journal: Cancers

Published: April 21, 2020

Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.

Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.

Journal: Leukemia

Published: March 01, 2020

Acute myeloid leukaemia in a case with Tatton-Brown-Rahman syndrome: the peculiar DNMT3A R882 mutation.

Acute myeloid leukaemia in a case with Tatton-Brown-Rahman syndrome: the peculiar DNMT3A R882 mutation.

Journal: Journal of medical genetics

Published: January 30, 2017

BCOR and BCORL1 mutations in pediatric acute myeloid leukemia.

BCOR and BCORL1 mutations in pediatric acute myeloid leukemia.

Journal: Haematologica

Published: January 18, 2015

Somatic thrombopoietin (THPO) gene mutations in childhood myeloid leukemias.

Somatic thrombopoietin (THPO) gene mutations in childhood myeloid leukemias.

Journal: International journal of hematology

Published: November 04, 2014

Showing 1-12 of 16

Last Updated: 09/26/2026